Regentis Biomaterials is a tissue repair company focused on developing and commercializing of innovative hydrogel platform for the repair of damaged tissue. The Gelrin hydrogel platform is the foundation for the company’s flagship product, GelrinC, a biodegradable implant for cartilage regeneration. The product received ISO certification and is currently undergoing clinical trials in Germany, Belgium and Israel.
Regentis is funded by Crossroad Fund, Medica Venture Partners, SPCVitalife, DSM Ventures and the Technion Investment Opportunities Fund.
www.regentis.co.il
Regentis is funded by Crossroad Fund, Medica Venture Partners, SPCVitalife, DSM Ventures and the Technion Investment Opportunities Fund.
www.regentis.co.il
Total raised: $25M
Investors 3
| Date | Name | Website |
| - | Crossroad | crossroad-... |
| - | DSM | dsm.com |
| - | SCP Vitali... | scpvitalif... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.02.2016 | Series D | $15M | - |
| 14.05.2012 | Series C | $10M | - |
Mentions in press and media 3
| Date | Title | Description |
| 11.02.2016 | Regentis Biomaterials Closes $15M Series D Funding | Regentis Biomaterials Ltd., a Princeton, New Jersey and Or Akiva, Israel-based developer of cartilage repair solutions, closed a $15m Series D funding. The round was led by Haisco Pharmaceutical Group, a Chinese pharmaceutical manufacturer,... |
| 14.05.2012 | Regentis Biomaterials Raises $10M in Series C Funding | Regentis Biomaterials Ltd., an Or Akiva, Israel and Princeton, NJ-based company that is developing a cartilage regeneration implant, has raised $10m in Series C funding. Backers include Royal DSM, Crossroad Fund, Medica Venture Partners, SC... |
| 14.05.2012 | Regentis Biomaterials Announces $10M | OR AKIVA, ISRAEL, Privately held company focused on developing proprietary hydrogels for tissue regeneration, announced that it has raised $10 million. >> Click here for more funding data on Regentis Biomaterials >> To expor... |